Key facts
- Everest Biolabs’s last known valuation is $17.0M (Mar 2026).
- It has raised $600K across 1 recorded rounds; the latest was Seed Round ($4.3M) in Feb 2026.
- Notable investors include MassVentures.
- Everest Biolabs has filed 1 Form D with the SEC, most recently Mar 2026 ($4.3M sold to 7 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Everest Biolabs
Funding rounds
1 roundsAbout Everest Biolabs
Developer of laboratory instruments and assay kits intended for extracellular vesicle isolation and analysis. The company's platform offers automated isolation instruments, size-exclusion chromatography columns with multiple gel types, ELISA kits for vesicle quantification and purity assessment, and compact readers for multi-well absorbance measurement, enabling biomedical researchers to conduct standardized extracellular vesicle research workflows.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2024
- Employees
- 8
- Website
- everestbiolabs.com/
- Ownership
- Privately Held (backing)
Everest Biolabs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Everest Biolabs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Everest Biolabs in its N-PORT filings yet. We sweep new filings monthly.